Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form
Copyright © 2023 Crudele, Garcia-Irigoyen, Cariello, Piglionica, Scialpi, Florio, Piazzolla, Suppressa, Sabbà, Gadaleta and Moschetta..
Objective: Increased Fibroblast Growth Factor-21 (FGF-21) circulating levels have been described in obesity. In this observational study, we analysed a group of subjects with metabolic disorders to unravel the putative link between visceral adiposity and FGF-21 serum levels.
Methods: Total and intact serum FGF-21 concentration was measured with an ELISA assay respectively in 51 and 46 subjects, comparing FGF-21 levels in dysmetabolic conditions. We also tested Spearman's correlations between FGF-21 serum levels and biochemical and clinical metabolic parameters.
Results: FGF-21 was not significantly increased in high-risk conditions such as visceral obesity, Metabolic Syndrome, diabetes, smoking, and atherosclerosis. Waist Circumference (WC), but not BMI, positively correlated with total FGF-21 levels (r=0.31, p <0.05), while HDL-cholesterol (r=-0.29, p <0.05) and 25-OH Vitamin D (r=-0.32, p <0.05) showed a significant negative correlation with total FGF-21. ROC analysis of FGF-21 in prediction of increased WC, showed that patients with total FGF-21 level over cut-off value of 161.47 pg/mL presented with impaired FPG. Conversely, serum levels of the intact form of FGF-21 did not correlate with WC and other metabolic biomarkers.
Conclusion: Our newly calculated cut-off for total FGF-21 according to visceral adiposity identified subjects with fasting hyperglycemia. However, waist circumference correlates with total FGF-21 serum levels but does not correlate with intact FGF-21, suggesting that functional FGF-21 does not necessarily relate with obesity and metabolic features.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 14(2023) vom: 03., Seite 1159127 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crudele, Lucilla [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
62031-54-3 |
|---|
| Anmerkungen: |
Date Completed 07.07.2023 Date Revised 18.07.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2023.1159127 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35910374X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35910374X | ||
| 003 | DE-627 | ||
| 005 | 20231226080149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2023.1159127 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM35910374X | ||
| 035 | |a (NLM)37409233 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crudele, Lucilla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Crudele, Garcia-Irigoyen, Cariello, Piglionica, Scialpi, Florio, Piazzolla, Suppressa, Sabbà, Gadaleta and Moschetta. | ||
| 520 | |a Objective: Increased Fibroblast Growth Factor-21 (FGF-21) circulating levels have been described in obesity. In this observational study, we analysed a group of subjects with metabolic disorders to unravel the putative link between visceral adiposity and FGF-21 serum levels | ||
| 520 | |a Methods: Total and intact serum FGF-21 concentration was measured with an ELISA assay respectively in 51 and 46 subjects, comparing FGF-21 levels in dysmetabolic conditions. We also tested Spearman's correlations between FGF-21 serum levels and biochemical and clinical metabolic parameters | ||
| 520 | |a Results: FGF-21 was not significantly increased in high-risk conditions such as visceral obesity, Metabolic Syndrome, diabetes, smoking, and atherosclerosis. Waist Circumference (WC), but not BMI, positively correlated with total FGF-21 levels (r=0.31, p <0.05), while HDL-cholesterol (r=-0.29, p <0.05) and 25-OH Vitamin D (r=-0.32, p <0.05) showed a significant negative correlation with total FGF-21. ROC analysis of FGF-21 in prediction of increased WC, showed that patients with total FGF-21 level over cut-off value of 161.47 pg/mL presented with impaired FPG. Conversely, serum levels of the intact form of FGF-21 did not correlate with WC and other metabolic biomarkers | ||
| 520 | |a Conclusion: Our newly calculated cut-off for total FGF-21 according to visceral adiposity identified subjects with fasting hyperglycemia. However, waist circumference correlates with total FGF-21 serum levels but does not correlate with intact FGF-21, suggesting that functional FGF-21 does not necessarily relate with obesity and metabolic features | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HDL cholesterol | |
| 650 | 4 | |a intact FGF21 | |
| 650 | 4 | |a visceral obesity | |
| 650 | 4 | |a vitamin D | |
| 650 | 4 | |a waist circumference | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 700 | 1 | |a Garcia-Irigoyen, Oihane |e verfasserin |4 aut | |
| 700 | 1 | |a Cariello, Marica |e verfasserin |4 aut | |
| 700 | 1 | |a Piglionica, Marilidia |e verfasserin |4 aut | |
| 700 | 1 | |a Scialpi, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Florio, Marilina |e verfasserin |4 aut | |
| 700 | 1 | |a Piazzolla, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Suppressa, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Sabbà, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Gadaleta, Raffaella Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Moschetta, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 14(2023) vom: 03., Seite 1159127 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:03 |g pages:1159127 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2023.1159127 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 03 |h 1159127 | ||